Targeted drug may shrink thyroid tumors before surgery
NCT ID NCT01709292
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug vemurafenib in 24 people with advanced papillary thyroid cancer that has a BRAF gene mutation. The drug aims to block this mutation to shrink tumors before surgery. Researchers will measure changes in tumor size and biomarkers in blood and tissue over 56 days. The goal is to see if the drug can make inoperable tumors removable and improve surgical outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAPILLARY THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic test may spare patients from unnecessary thyroid surgery
- Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
- Can an immune booster make radioiodine more effective against thyroid cancer?
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can math make thyroid hormone therapy more precise?
- Can AI help surgeons see thyroid cancer more clearly?